SCHEMBL3400966

SCHEMBL3400966

NCc1ccc(F)c(Br)c1.NCc1ccc(F)c(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
LOXL2 Q9Y4K0 3/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PNMT P11086 1/20 0.40
TAAR1 Q96RJ0 3/20 0.39
HRH3 Q9Y5N1 1/20 0.39
HTR2A P28223 1/20 0.38
PARP1 P09874 2/20 0.38
ABAT P80404 1/20 0.36
ENPP2 Q13822 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51845 1.00 KDM4E (0.47) KDM4ELOXL2CYP1A2CYP2D6CYP2C9
Hydrochloric Acid SCHEMBL148514 0.98 KDM4E (0.46) KDM4ELOXL2CYP1A2CYP2D6CYP2C9
SCHEMBL1363945 0.84 TAAR1 (0.52) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL17823096 0.83 TAAR1 (0.50) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL855443 0.82 LOXL2 (0.46) LOXL2PNMTTAAR1HRH3HTR2A
Hydrochloric Acid SCHEMBL29567776 0.80 LOXL2 (0.44) LOXL2TAAR1HRH3HTR2ACA1
Hydrochloric Acid SCHEMBL16037704 0.80 LOXL2 (0.44) LOXL2TAAR1HRH3HTR2ACA1
SCHEMBL11244115 0.79 KDM4E (0.49) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL29418197 0.79 CYP1A2 (0.53) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL333551 0.79 CYP1A2 (0.53) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071588-B2 Dual pharmacophores—PDE4-muscarinic antagonistics GLAXO GROUP LIMITED (GB) 2011-12-06 US disclosed
EP-2247184-A1 DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS Glaxo Group Limited (GB) 2010-11-10 EP disclosed
WO-2009100167-A1 DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS GLAXO GROUP LIMITED (GB) 2009-08-13 WO disclosed
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics PDE4A, PDE4B, PDE1A KDM4E 1404/4885LOXL2 1350/4885CYP1A2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.